Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

NCT05807542 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Esophagus Cancer

Interventions

DRUG: Tislelizumab
DRUG: Paclitaxel-albumin
DRUG: Carboplatin

Sponsor

Shanghai Zhongshan Hospital